new gsk presentation

• Skip to Content
• Skip to Search

Speeches and presentations

Search through our archive of speeches and presentations from conferences and events.

Visit our corporate reporting archive for our Annual Reports.

For quarterly results materials visit quarterly results .

26 March 2024

BNP Paribas Exane Healthcare Conference, Virtual

Julie Brown, Chief Financial Officer, participated in a fireside chat at the BNP Paribas Exane Healthcare Conference which took place on Tuesday, 26 March 2024.

19 March 2024

ESG Investor Education Event (ESG Performance Report)

GSK’s VP of Reputation and Responsible Business, Clare Griffin, and VP of Sustainability, Claire Lund, presented a 45 minute virtual event focused on the newest set of ESG data for the company – the 2023 ESG Performance Report.

• Watch the webcast
• Presentation (PDF - 325.0KB)
• Transcript (PDF - 90.8KB)
• Download all

Berenberg UK Corporate Conference, Watford

Julie Brown, Chief Financial Officer, attended the Berenberg UK Corporate Conference on Tuesday, 19 March 2024.

04 March 2024

TD Cowen Healthcare Conference

Luke Miels, Chief Commercial Officer, participated in a fireside chat at TD Cowen's Healthcare Conference taking place on Monday 4 March at 2:50pm ET / 7:50pm GMT.

• Listen to the webcast

28 February 2024

UBS European Healthcare Conference, London

Julie Brown, Chief Financial Officer, attended the London UBS European Healthcare Conference on Tuesday, 28 February 2024.

09 January 2024

42nd annual JP Morgan Healthcare Conference

Emma Walmsley, Chief Executive Officer, participated in the 42nd annual JP Morgan Healthcare Conference on Tuesday 9 January at 07:30-08:10am PST / 15:30-16:10 GMT. The 40 minute session included a presentation and a moderated Q&A discussion.

• JP Morgan Healthcare Conference presentation (PDF - 1.0MB)
• JP Morgan Healthcare Conference transcript (PDF - 81.2KB)

30 November 2023

Getting ahead of Respiratory Diseases with GSK management

GSK management held a virtual event on 30 November at 8:00 AM EST / 1:00 PM GMT. The event featured a presentation and an interactive Q&A session. A replay is available on demand.

• Watch the recording
• Getting ahead of respiratory diseases presentation (PDF - 4.6MB)
• Getting ahead of respiratory diseases transcript (PDF - 134.0KB)

29 November 2023

Evercore ISI HealthCONx Conference

Phil Dormitzer, SVP and Global Head Vaccines R&D and Infectious Disease Research, discussed the progress being made in vaccine innovation during a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, 29 November 2023, 12:30pm UK / 7:30am ET.

Redburn Atlantic CEO Conference

Luke Miels, Chief Commercial Officer, discussed the progress being made at GSK during a fireside chat at the Redburn Atlantic CEO Conference on Wednesday, 29 November 2023 at 9:00am UK.

16 November 2023

Jefferies London Healthcare Conference

Tony Wood, Chief Scientific Officer, participated in a fireside chat at the Jefferies London Healthcare Conference on Thursday, 16 November at 9:00am GMT.

28 September 2023

Getting ahead of HIV with ViiV Healthcare management

ViiV Healthcare management held a virtual event on 28 September at 9:00 AM EDT / 2:00 PM BST. The event, "Getting ahead of HIV," featured a presentation and an interactive Q&A. A recording of the session is available on YouTube.

• Getting ahead of HIV together presentation (PDF - 1.4MB)
• Getting ahead of HIV together transcript (PDF - 231.8KB)

14 September 2023

BofA 2023 Global Healthcare Conference

Emma Walmsley, Chief Executive Officer, participated in a fireside chat at the BofA Global Healthcare Conference on Thursday 14 September at 09:05 BST.

07 September 2023

Citi’s 18th Annual BioPharma Conference

Phil Dormitzer, SVP, Head of Vaccines R&D joined Andrew Baum in a fireside chat at Citi’s 18th Annual BioPharma Conference which took place Thursday, September 7th at 8:50am ET/1:50pm UK.

27 June 2023

Getting ahead of Infectious Disease with GSK management

The virtual event featured a presentation, four breakout sessions and an interactive Q&A. Recordings of all sessions are available on YouTube.

• Watch the recordings
• Opening and plenary session (PDF - 2.6MB)
• Breakout 1 - Seasonal respiratory viruses (PDF - 1.6MB)
• Breakout 2 - Bacterial and fungal infections (PDF - 1.7MB)
• Breakout 3 - Chronic viral infections (PDF - 784.1KB)
• Breakout 4 - Delivering health impact at scale (PDF - 1.8MB)

13 June 2023

Goldman Sachs’ 44th Annual Global Healthcare Conference

Tony Wood, Chief Scientific Officer, discussed progress made in R&D during a fireside chat on Tuesday, 13 June at 9:20am PT/12:20pm ET/5:20pm UK during Goldman Sachs’ 44th Annual Global Healthcare Conference, in Dana Point, California.

• Download audio (MP3 - 7.7MB)

06 June 2023

ESG Investor Education Event (Clinical Trial Diversity)

During the 45 minute session Alberto Fernandez, SVP of Global Clinical Operations at GSK and Dr. Kimberly Smith, SVP and Head of R&D at ViiV Healthcare, provided insights on the importance of clinical trial diversity including support from a 17-year retrospective study. During the session, the leaders also provided an overview of GSK’s work to ensure clinical trials reflect the populations most impacted by a disease and explored a HIV case study that demonstrated the power of clinical trial diversity in action. The presentation was followed by an opportunity for audience Q&A.

• Download audio
• Clinical Trial Diversity presentation (PDF - 1.8MB)

10 January 2023

41st annual JP Morgan Healthcare Conference

Emma Walmsley, Chief Executive Officer, presented at the 41st annual JP Morgan Healthcare Conference on Tuesday 10 January at 07:30-08:10am PT / 15:30-16:10 GMT. The 40 minute session included a presentation and a moderated Q&A discussion. 

• Download audio (MP3 - 17.6MB)
• JP Morgan Healthcare Conference Presentation (PDF - 5.0MB)
• JP Morgan Healthcare Conference Transcript (PDF - 149.8KB)

30 November 2022

Deborah Waterhouse, Chief Executive Officer of ViiV Healthcare, and Dr. Kimberly Smith, Head of R&D at ViiV Healthcare, discussed the progress being made in HIV innovation during a fireside chat at the Evercore ISI HealthCONx Conference Wednesday, November 30 th , 1pm UK / 8:00am ET .

16 November 2022

David Redfern, Chief Strategy Officer, participated in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, 16 November 2022 at 09:45 GMT.

28 October 2022

Response to Investor Forum Letter

GSK’s response to an Investor Forum letter, regarding GSK’s redefined operating model post-Demerger.

• GSK’s response to an Investor Forum letter (PDF - 232.4KB)

21 October 2022

Investor science event: Getting ahead of respiratory syncytial virus in older adults

After presenting the positive AReSVi-006 pivotal phase III results for our RSV (respiratory syncytial virus) older adults vaccine candidate at IDWeek 2022, GSK management hosted an investor science event on 21 October 2022.

• GSK RSV Investor Science Event ID Week 2022 (PDF - 1.6MB)
• GSK RSV Older Adults Investor Briefing Document (PDF - 1.5MB)
• GSK Investor Science Event - Transcript (PDF - 213.9KB)

16 September 2022

BofA 2022 Global Healthcare Conference

Emma Walmsley, CEO, participated in a fireside chat at the BofA Global Healthcare Conference on Friday 16 September at 0815 BST.

07 September 2022

Citi 17th Annual BioPharma Conference

Roger Connor, President Global Vaccines & Global Health and Phil Dormitzer, SVP, Head of Vaccines R&D joined Andrew Baum in a fireside chat at Citi’s 17th Annual BioPharma Conference which took place Wednesday, September 7 at 1:50pm ET/6:50pm UK. 

14 June 2022

dbAccess Global Consumer Conference 2022

Tobias Hestler, CFO GSK Consumer Healthcare participated in a fireside chat at the dB Access Global Consumer Conference on 14th June 2022 at 14:45pm BST (15:45pm CEST, 9:45am EDT).

13 June 2022

Goldman Sachs 43rd Annual Global Healthcare Conference

Deborah Waterhouse, CEO, ViiV Healthcare, and Dr. Kimberly Smith, Head of R&D, ViiV Healthcare, discussed progress being made in the HIV space during a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference, Monday, June 13 th  at 10:00pm UK / 5:00pm ET

24 May 2022

UBS Global Healthcare Conference 2022

Dr. Kimberly Smith, Head of R&D, ViiV Healthcare, discussed progress being made in HIV innovation during a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 24 th  at 2:15pm UK / 9:15am ET.​

20 May 2022

JPMorgan CEO Consumer Staples fireside chat series

Brian McNamara, CEO Designate of Consumer Healthcare, participated in a fireside chat with JPMorgan analyst Celine Pannuti as part of her series of discussions with consumer staples CEOs. In the conversation Brian discussed the growth outlook across various consumer health categories, recent innovation trends and progress towards becoming a standalone company. 

• Watch the webcast. Access code: 368408

05 April 2022

ESG Investor Education Event (Environment)

Claire Lund, Vice President Environmental Sustainability, hosted our first ESG Investor Education Event  focusing on our environment strategy, 5 April 2022 at 15:00 BST / 10:00 EDT.

• Watch the replay
• Presentation (PDF - 3.4MB)
• Transcript (PDF - 228.8KB)

09 March 2022

UBS Global Consumer and Retail Conference 2022

Tobias Hestler, CFO Designate of Consumer Healthcare, participated in a fireside chat at the UBS Global Consumer and Retail Conference hosted by UBS analyst Guillaume Delmas.

07 March 2022

Cowen 42nd Annual Health Care Conference

Hal Barron, Chief Scientific Officer and President R&D, discussed the progress GSK is making in R&D during a fireside chat at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, 7 March 2022 at 4:10pm UK/11:10pm ET.

28 February 2022

GSK Consumer Healthcare Capital Markets Day

GSK's Consumer Healthcare Capital Markets Day took place on Monday 28 February 2022. This event provided details on our strategy, brands, capabilities and operations, as well as detailed financial information and future growth ambitions ahead of the proposed listing on the London Stock Exchange following the anticipated demerger from GSK mid-2022.

• Haleon Capital Markets Day All Presentation Slides (PDF - 12.4MB)
• Haleon Capital Markets Day Full Presentation Transcript (PDF - 307.3KB)
• Haleon Factsheet (PDF - 960.4KB)
• Capital Markets Day Webcast platform

10 February 2022

FCLT Global presents “Investing in Healthcare Innovations: A Case Study of Multi-stakeholder Capitalism in Practice"

Roger Connor, President Global Vaccines & Global Health, particpated in a panel hosted by FCLT Global on Thursday, February 10 th  at 8:00am ET/1:00pm GMT.  The panel focused on navigating the complexity of long-term strategies and investment since financing healthcare advancements, and particularly vaccine development, became central priority with the onset of COVID19.

• Watch the Webinar

11 January 2022

JP Morgan Healthcare Conference 2022

Emma Walmsley, Chief Executive Officer, presented at the 40th annual JP Morgan Healthcare Conference on Tuesday 11 January at 07:30-08:10am ET / 12:30-13:10 GMT. The 40 minute session included a presentation and a moderated Q&A discussion. 

• Listen to the audio
• JP Morgan Healthcare Conference Presentation
• JP Morgan Healthcare conference transcript (PDF - 448.6KB)

06 January 2022

Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference

Emma Walmsley, Chief Executive Officer, participated in the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top, on Thursday, 6 January 2022 at 8:00am ET.

02 December 2021

Morgan Stanley ESG Insights Conference 2021

Harmony Garges, SVP and Chief Medical Officer ViiV Healthcare, presented at the virtual Morgan Stanley ESG Insights Conference and provided an overview of ViiV’s mission to leave no person living with HIV behind and how it aligns with ViiV’s ESG efforts.

• Morgan Stanley ESG Insights Conference presentation

01 December 2021

Redburn CEO conference 2021

Brian McNamara, CEO of GSK Consumer Healthcare, participated in a virtual fireside chat at the 2021 Redburn CEO Conference. He provided an overview of our business and broader industry.

29 November 2021

Meet GSK management: getting ahead of HIV

GSK hosted a ‘Meet GSK management’ event on 29 November 2021 at 15:00 GMT / 10:00 EST.

• Getting ahead of HIV presentation (PDF - 10.7MB)
• Getting ahead of HIV transcript (PDF - 194.2KB)
• Webcast registration

09 November 2021

UBS European Conference 2021

Tobias Hestler, CFO GSK Consumer Healthcare, participated in a virtual fireside chat at the UBS European Conference hosted by analyst Guillaume Delmas.

07 November 2021

Investor science event: ASN Kidney Week 2021

GSK held an investor science event for daprodustat’s ASCEND Phase III programme at 12 noon EST/ 5pm GMT on 7 November 2021.

• Register to the webcast
• ASN 2021 presentation
• ASN 2021 transcript (PDF - 155.1KB)

07 October 2021

The Investor Forum

Sir Jonathan Symonds, Chairman, and Manvinder Singh Banga, Senior Independent Non-Executive Director, participated in an Investor Forum meeting on Thursday 7 October 2021.

• Presentation slides

06 October 2021

Guggenheim 2nd Annual Vaccine and Infectious Disease Day

Rino Rappuoli, Senior Vice President Global Head of Vaccines R&D, participated in a fireside chat at Guggenheim’s 2 nd Annual Vaccine and Infectious Disease Day which took place on Wednesday 6 October 2021 at 1:00pm ET. 

22 September 2021

Bernstein Annual Pan European Strategic Decisions Conference

Tobias Hestler, CFO for GSK Consumer Healthcare participated in a virtual fireside chat at the Bernstein Annual Pan European Strategic Decisions Conference.

17 September 2021

BofA 2021 Global Healthcare Conference

Emma Walmsley, CEO, participated in a fireside chat at the BofA Global Healthcare Conference on Friday 17 September at 0815 BST.

10 September 2021

Barclay’s Global Consumer Staples conference

Brian McNamara, CEO GSK Consumer Healthcare, joined a virtual fireside chat hosted by Barclay’s analyst, Iain Simpson.  He provided an overview of the Consumer Healthcare business and our category leading brands. 

09 September 2021

Citi 16th Annual Biopharma Conference

Dr. Kimberly Smith, Head of R&D, ViiV Healthcare participated in a fireside chat at Citi’s 16th Annual Biopharma Conference taking place on Thursday 9 September 2021 at 18:25 UK / 1:25pm EDT. Dr. Smith provided an update on ViiV Healthcare’s progress in advancing HIV science and R&D.

29 June 2021

Guggenheim’s Biopharma Strategy Series

Hal Barron, Chief Scientific Officer and President R&D, joined a virtual fireside chat hosted by Guggenheim analyst Seamus Fernandez at Guggenheim’s Biopharma Strategy Series.

The event, 'Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation' took place Tuesday, 29 June 2021 at 19:00 BST / 14:00 EDT, during which he provided an update on the progress GSK is making in R&D.

23 June 2021

New GSK Investor update

Emma Walmsley, CEO, and other members of CET hosted a virtual investor update at 14:00-17:30 BST on Wednesday 23 June. The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.

• Presentation slides (PDF - 7.9MB)
• Presentation transcript (PDF - 269.5KB)
• Q&A transcript (PDF - 150.3KB)
• Epidemiology data (PDF - 3.3MB)
• Clinical trials summary (PDF - 3.5MB)
• Link to the event webcast

10 June 2021

Exane BNP Paribas 23rd European CEO Conference

Brian McNamara, CEO, GSK Consumer Healthcare, presented at the conference and provided an introduction to GSK Consumer Healthcare and outlined our purpose, strategy, category-leading brands and capabilities, as well as an overview of the consumer healthcare sector.

• Exane June 21 Show File Vf (PDF - 2.5MB)

08 June 2021

CECP Biopharma Investor Forum

Emma Walmsley, CEO, presented at CECP’s Biopharma Investor Forum on Tuesday 8 June at 8:40 EST/13:40 BST, during which she provided an overview on our approach to ESG. The presentation was followed by a moderated Q&A session.

• CECP presentation slides (PDF - 505.4KB)
• CECP presentation script

10 March 2021

Barclays Global Healthcare Conference 2021

Deborah Waterhouse, CEO of ViiV Healthcare, participated in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 10 at 8:35am ET/1:35pm GMT, during which she provided an update on the progress GSK is making in the HIV space.

01 March 2021

Cowen 41st Annual Health Care Conference

Hal Barron, Chief Scientific Officer and President R&D, participated in a fireside chat at the Cowen 41st Annual Health Care Conference on Monday, March 1 2021 at 5:20pm GMT /12:20pm ET, during which he discussed updates on the progress GSK is making in R&D.

11 February 2021

Guggenheim Healthcare Talks 2021

Axel Hoos, GSK Senior Vice-President Oncology R&D, joined a Fireside Chat with Seamus Fernandez at the Guggenheim Healthcare Talks 2021 Oncology Days, Thursday, February 11, at 10AM ET, where the duo discussed GSK Oncology R&D progress.

11 January 2021

39th annual JP Morgan Virtual Healthcare Conference

Hal Barron, Chief Scientific Officer and President R&D, presented at the 39th annual JP Morgan Virtual Healthcare Conference on Tuesday 12 January at 10:50-11:30am ET / 15:50-16:30 GMT.  The presentation was followed by a Q&A session. 

• Gsk Jpm 2021 Final 12012021 (PDF - 689.9KB)
• 39Th Annual Jp Morgan Virtual Healthcare Conference Transcript (PDF - 125.9KB)

05 January 2021

Goldman Sachs 13th Annual Healthcare Unscripted CEOs Conference

Emma Walmsley, CEO, hosted a fireside chat at the Goldman Sachs 13th annual healthcare unscripted CEOs conference on Tuesday 5 January at 12:00 GMT

09 December 2020

Morgan Stanley ESG Insights Conference

Phil Thomson, President Global Affairs, hosted a fireside chat at the Morgan Stanley ESG Insights Conference on Wednesday, 9 December 2020 at 15:25 GMT / 10:25am EST.

• Morgan Stanley ESG Insights Conference webcast
• Morgan Stanley ESG Conference presentation

01 December 2020

Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at Evercore ISI HealthCONx Conference on Tuesday, 1 December 2020 at 13:00 GMT / 8:00am EST, during which provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

• Evermore ISI HealthCONx webcast

22 October 2020

Investor and analyst call to discuss RSV vaccines data

GSK held an investor and analyst call hosted by Hal Barron, Chief Scientific Officer and President R&D, Roger Connor, President, GSK Vaccines, and Emmanuel Hanon, SVP and Head of Vaccines R&D, and discussed data on two respiratory syncytial virus (RSV) vaccine candidates to be presented at ID Week.

This event took place on Thursday 22 October at 3:30pm CET / 2:30pm BST / 9:30am EDT.

• ID Week RVS presentation
• ID Week RVS call transcript (PDF - 99.6KB)

17 September 2020

BofA Global Healthcare Conference

Emma Walmsley, CEO, hosted a fireside chat at the BofA Global Healthcare Conference on Thursday 17 September at 0815 BST.

09 September 2020

Citi 15th Annual Biopharma Conference

Hal Barron, Chief Scientific Officer and President R&D, will host a fireside chat at the Citi 15th Annual Biopharma Conference taking place Wednesday 9 September 2020 at 16:40 BST/11:40am EDT, during which he will provide an update on the progress GSK is making in the R&D pipeline.

• Citi 15th Annual Biopharma Conference Webcast

09 July 2020

Investor and analyst call to discuss HIV Prevention Treatment Network 083 study

GSK held an investor/analyst call hosted by David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO, ViiV Healthcare and Dr. Kimberly Smith, Head of R&D, ViiV Healthcare to discuss the final efficacy analysis from the global HIV Prevention Treatment Network (HPTN) 083 study evaluating investigational long-acting cabotegravir for HIV prevention.

This event took place on: Thursday 9 July at 14:00 BST / 09:00 EDT

• CAB LA For PREP Presentation (PDF - 2.2MB)
• CAB LA For PREP call transcript (PDF - 139.1KB)

13 February 2020

Guggenheim Healthcare Talks Idea Forum, New York City

Axel Hoos, Senior Vice-President Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum, Oncology Day, held in New York City on Thursday, February 13th, during which he provided an update on GSK Oncology R&D progress.

14 January 2020

38th annual JP Morgan Healthcare Conference, San Francisco

Emma Walmsley, CEO, presented at the 38th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 14 January, and provided an overview of GSK’s priorities and the progress the company made during 2019.  The presentation was followed by a Q&A session. 

• Presentation by Emma Walmsley at the JP Morgan 2020 Healthcare conference (PDF - 651.1KB)

17 December 2019

Investor and Analyst call from DREAMM-2 data

On Tuesday, 17 December 2019 at 17:00 GMT / 12:00 EST, Hal Barron, Chief Scientific Officer and President of R&D, Luke Miels, President Pharmaceuticals and Axel Hoos, SVP Oncology R&D hosted an investor/analyst conference call to discuss GSK’s pivotal DREAMM-2 data on belantamab mafodotin (GSK’916).

• DREAMM-2 data presentation
• DREAMM-2 data transcript (PDF - 592.3KB)

30 September 2019

Investor and Analyst call from ESMO 2019

On Monday, 30 September 2019, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of the PRIMA data on Zejula (niraparib) and the INDUCE-1 data on GSK’609 (ICOS) at the 2019 European Society for Medical Oncology (ESMO) congress. The call also featured participation from an external expert in ovarian cancer and other GSK senior oncology leaders.

• ESMO Presentation (PDF - 1.6MB)
• ESMO transcript (PDF - 208.7KB)

26 September 2019

GSK Vaccines Investor Event

Roger Connor, President, GSK Vaccines, hosted an educational session on GSK’s Vaccines business at our manufacturing site in Wavre, Belgium on Thursday 26 September at 13:30 CET / 12:30 BST / 7:30 EDT.

• Analyst Webcast
• Vaccines Waver IR event slides
• Investor event transcript (PDF - 155.8KB)

12 June 2019

Goldman Sachs’ 40th Annual Global Healthcare Conference, California

Hal Barron, Chief Scientific Officer and President R&D, hosted a fireside chat at Goldman Sachs’ 40 th  Annual Global Healthcare Conference, which took place in Rancho Palos Verdes, California on Wednesday 12 June, during which he has provided an update on the progress being made in GSK’s R&D organisation.

06 June 2019

Jefferies 2019 Healthcare Conference, New York

David Redfern, Chief Strategy Officer of GSK and Chairman of ViiV Healthcare, and Deborah Waterhouse, CEO of ViiV Healthcare, hosted a fireside chat at the Jefferies 2019 Healthcare Conference in New York on Thursday 6 June, during which they provided an update on the progress GSK and ViiV Healthcare have made this year.

04 June 2019

Bernstein Consumer Healthcare & Nutrition Seminar, London

Tobias Hestler, CFO GSK Consumer Healthcare, hosted a fireside chat at the Bernstein Consumer Healthcare & Nutrition Seminar in London on Tuesday 4 June during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

• Bernstein Consumer Healthcare and Nutrition Seminar - slides

30 April 2019

ViiV Healthcare analyst call

David Redfern, Chairman ViiV Healthcare, Deborah Waterhouse, CEO ViiV Healthcare and Dr Kimberly Smith, VP Global Research & Medical Strategy hosted a ViiV Healthcare analyst call on Tuesday 30 April to discuss ViiV Healthcare’s recent regulatory activities and provide an update on the pipeline.

• Fuelling Our Future Growth - Slides (PDF - 1.7MB)
• ViiV Healthcare investor call - transcript (PDF - 127.4KB)

12 March 2019

Cowen & Co. 39th Annual Health Care Conference, Boston

Luke Miels, President Global Pharmaceuticals, hosted a fireside chat at the Cowen & Co. 39th Annual Health Care Conference 2019 in Boston on Tuesday 12 March, during which he provided an update on the progress GSK is making in the global pharmaceuticals and vaccines business.

28 February 2019

SVB Leerink Global Healthcare Conference, New York

Brian McNamara, CEO GSK Consumer Healthcare, hosted a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference that took place in New York City on Thursday 28 February during which he provided an update on the Consumer Healthcare business and the formation of a new, world-leading Consumer Healthcare joint venture.

• GSK Consumer Healthcare - Slides (PDF - 819.6KB)

14 February 2019

Guggenheim Healthcare Talks Idea Forum, New York

Axel Hoos, SVP Oncology R&D, hosted a Fireside Chat at the Guggenheim Healthcare Talks Idea Forum - Oncology Day held in New York City on Thursday 14 February during which he provided an update on GSK Oncology R&D progress.

• GSK Oncology R&D Update - Slides (PDF - 295.2KB)

08 January 2019

37th annual JP Morgan Healthcare Conference, San Francisco

Emma Walmsley, CEO, gave a presentation at the 37th annual JP Morgan Healthcare Conference in San Francisco on Tuesday 8 January, providing an overview of GSK’s priorities and the progress the company made during 2018.

• JPM 2019 Emma Walmsley Presentation - Slides (PDF - 273.9KB)

19 December 2018

Analyst call on formation of new Consumer Healthcare JV

On Wednesday 19 December 2018, GSK announced an agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Brian McNamara, CEO GSK Consumer Healthcare and Simon Dingemans, Chief Financial Officer.

• Formation Of new Consumer Healthcare JV - Slides (PDF - 1.1MB)
• Formation of new Consumer Healthcare JV - transcript (PDF - 226.2KB)
• GlaxoSmithKline plc and pfizer Inc to form new world-leading Consumer Healthcare joint ventur

10 December 2018

ViiV Meet the Management, London

David Redfern, Chairman ViiV Healthcare and Deborah Waterhouse, CEO ViiV Healthcare along with members of the ViiV Healthcare leadership team hosted a ViiV Healthcare Investor Event on Monday 10 December in London. The event included presentations from David, Deborah, Dr Kimberly Smith Global Research & Medical Strategy, Eric Dube Head of North America and Dr John Pottage Chief Scientific & Medical Officer and was followed by a Q&A session

• ViiV Meet The Management - Slides (PDF - 4.9MB)
• ViiV Meet The Management - transcript (PDF - 186.8KB)

05 December 2018

Citi 2018 Global Healthcare Conference, New York

Hal Barron, Chief Scientific Officer and President, R&D hosted a fireside chat at the Citi 2018 Global Healthcare Conference held in New York City on Wednesday 5 December, in which he provided an overview of GSK’s R&D priorities and progress made during 2018.

03 December 2018

Analyst call on agreement to acquire TESARO

On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.

• GSK Acquisition Of TESARO Investor Call - Slides (PDF - 428.3KB)
• Agreement To Acquire Tesaro Investor Call - transcript (PDF - 308.6KB)
• GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company

28 November 2018

Evercore ISI HealthConX Conference, Boston

Deborah Waterhouse, CEO, and Dr Kimberly Smith, Head of Global Research and Medical Strategy, ViiV Healthcare, hosted a fireside chat at the Evercore ISI HealthConX Conference held in Boston, Massachusetts on Wednesday 28 November, during which they provided an overview of ViiV’s priorities and progress made during 2018.

23 October 2018

Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR

On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.

• GSK' 165: anti-GM-CSF antibody - slides
• GSK'165 anti-GM-CSF antibody - transcript (PDF - 99.0KB)

21 September 2018

Consumer Healthcare investor event, New Jersey

Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science, Consumer Sensory and R&D labs, as well as presentations from Brian McNamara, Marc Speichert, SVP Digital and Richard Slater, SVP R&D, followed by a Q&A session.

• Consumer Healthcare investor event - slides (PDF - 4.5MB)
• Consumer Healthcare investor event - transcript (PDF - 165.6KB)

20 September 2018

CECP CEO Investor Forum

Emma Walmsley, CEO, spoke at CECP’s CEO Investor Forum on Thursday 20 September 2018 about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.

• Watch the webcast on YouTube

13 September 2018

Bank of America Merrill Lynch Global Healthcare Conference, London

Emma Walmsley, CEO, gave a presentation at the Bank of America Merrill Lynch Global Healthcare Conference in London on Thursday 13 September 2018 in which she provided an overview of GSK’s priorities and progress made during 2018.

24 July 2018

GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update

On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.

The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.

• GEMINI Investor & Analyst Update (PDF - 777.0KB)
• GEMINI call transcript (PDF - 125.8KB)

13 June 2018

Goldman Sachs 39th Annual Healthcare Conference, California

David Redfern, Chief Strategy Officer, hosted a fireside chat at the Goldman Sachs 39th Annual Healthcare Conference in Rancho Palos Verdes, California on Wednesday 13 June, in which he provided an overview of GSK’s priorities and progress made during 2018.

06 June 2018

Jefferies 2018 Healthcare Conference, New York City

David Redfern, Chief Strategy Officer, hosted a fireside chat at the Jefferies 2018 Healthcare Conference in New York City on Wednesday 6 June, in which he provided an overview of GSK’s priorities and progress made during 2018.

27 March 2018

Consumer Healthcare Update, London

On Tuesday, 27 March 2018, GSK reached an agreement with Novartis to acquire full ownership of the Consumer Healthcare business. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer and Brian McNamara, CEO, Consumer Healthcare.

• Consumer Healthcare Update - Analyst Call slides (PDF - 929.5KB)
• GSK Consumer Healthcare Update - transcript
• GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

09 January 2018

36th annual JP Morgan Healthcare Conference, San Francisco, US

Emma Walmsley, CEO, gave a presentation at the 36th annual JP Morgan Healthcare Conference in San Francisco about our business outlook, as well as our latest product approvals and advances in our pipeline.

• 2018 JPM Emma Walmsley presentation (PDF - 699.0KB)
• 2018 JPM Emma Walmsley presentation transcript (PDF - 54.7KB)
• 2018 JPM Emma Walmsley Q&A transcript (PDF - 65.9KB)

12 December 2017

GSK Oncology Investor & Analyst Update

On Tuesday, 12 December 2017, GSK hosted an investor conference call following the presentation of scientific and clinical data on GSK2857916, GSK's anti-BCMA (B-cell Maturation Antigen) antibody-drug conjugate presented at the 59th American Society of Hematology (ASH) annual meeting. The call was hosted by Luke Miels, President, GSK Global Pharmaceuticals and Axel Hoos, SVP and Therapy Area Head of Oncology R&D. The call also featured participation from an external expert in multiple myeloma.

• GSK Oncology Invester & Analyst Update - slides (PDF - 800.0KB)
• GSK Oncology Invester & Analyst Update - transcript

07 December 2017

Citi Global Healthcare Conference, New York

Axel Hoos, SVP – Oncology R&D, participated in a fireside chat at the Citi Global Healthcare Conference on December 7 in New York.

• Citi Global Healthcare Conference - transcript (PDF - 145.1KB)

30 November 2017

Evercore conference, Boston

David Redfern, Chief Strategy Officer and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare and Kim Smith, Vice President, Global Medical Strategy, ViiV Healthcare, participated in a fireside chat at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston on Thursday, November 30.

• Evercore conference - transcript (PDF - 88.1KB)

29 November 2017

Consumer Healthcare investor event

Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science and Consumer Sensory labs, as well as presentations from Brian McNamara and Richard Slater, SVP, R&D Consumer Healthcare, followed by a Q&A session.

• Consumer Healthcare investor event - slides
• Consumer Healthcare investor event - transcript (PDF - 92.2KB)

26 July 2017

Investor event, London 2017

The investor event outlined the Group’s key priorities including presentations from Emma Walmsley, CEO, and Simon Dingemans, CFO.

• Emma Walmsley slides: Key Priorities (PDF - 864.3KB)
• Simon Dingemans slides: Q2 and fiannacial outlook (PDF - 509.3KB)
• Investor event full transcript (PDF - 173.6KB)

08 March 2017

Cowen 37th Annual Healthcare Conference

Axel Hoos, SVP – Oncology R&D, gave a presentation at the Cowen and Company 37 th  Annual Health Care Conference  in Boston. Axel provided an overview of GSK’s Oncology strategy and pipeline.

• Cowen 37th Annual Healthcare Conference - slides (PDF - 1.3MB)
• Cowen 37th Annual Healthcare Conference - transcript (PDF - 84.2KB)

15 February 2017

Investor event at CROI 2017, Seattle

ViiV Healthcare Chairman David Redfern, CEO Dominique Limet and Chief Scientific and Medical Officer John Pottage, hosted an investor event following the presentation of the SWORD Phase III data at the Conference on Retroviral and Opportunistic Infections.

• HIV analyst call presentation (PDF - 938.4KB)
• CROI analyst call transcript (PDF - 437.5KB)

10 January 2017

35th annual JP Morgan Healthcare Conference, San Francisco, USA

Dr Patrick Vallance, President, R&D gave a presentation at the 35th annual JP Morgan Healthcare Conference in San Francisco, providing an overview of the company’s pharmaceutical pipeline.

• 2017 JPM Patrick Vallance presentation (PDF - 1.1MB)
• 2017 JPM Patrick Vallance transcript (PDF - 176.9KB)

29 November 2016

Meet the Vaccines management

Luc Debruyne and his leadership team hosted an investor event to review the Vaccines business. This event included a tour of the Wavre site, presentations from Luc Debruyne, Thomas Breuer, Manu Hanon and John McGrath, followed by a Q&A session.

• GSK vaccines meet the management - slides (PDF - 4.9MB)
• GSK vaccines meet the management - transcript (PDF - 325.9KB)

19 September 2016

HIV and ViiV Healthcare presentation to Goldman Sachs

Seminar on the evolving scientific and commercial landscape for HIV and ViiV Healthcare. Presentation by Dr Dominique Limet and Dr John Pottage followed by a Q&A session.

• Goldman Sachs seminar on HIV And ViiV healthcare presentation (PDF - 1.3MB)
• Goldman Sachs seminar on HIV And ViiV healthcare transcript (PDF - 439.1KB)

02 September 2016

Meet The Respiratory Management event

Prior to the 2016 ERS conference, senior respiratory leaders Eric Dube, Neil Barnes and Dave Allen hosted an investor event with presentations and a Q&A session to review the Respiratory business.

• Meet the respiratory management presentation (PDF - 3.3MB)
• Meet the respiratory management transcript (PDF - 282.9KB)

08 June 2016

Goldman Sachs 37th Annual Global Healthcare Conference

Simon Dingemans, Chief Financial Officer, participated in a fireside chat to discuss progress on GSK’s business strategy and addressed questions before a large group of investors at the Goldman Sachs Conference in California on Wednesday, 8 June 2016.

• Goldman Sachs 37th annual global healthcare conference (PDF - 92.2KB)

24 February 2016

Citi Healthcare Bus Tour, New York

Dr. Axel Hoos, SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno-Oncology, hosted an investor event organized by Citi at their offices in New York. Axel provided an overview of GSK’s strategy and pipeline in Immuno-Oncology.

• Dr Axel Hoos transcript (PDF - 863.9KB)

10 February 2016

Leerink Partners 5th Annual Global Healthcare Conference

Simon Dingemans, Chief Financial Officer, addressed questions in front of a large group of US investors at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10 in New York. Simon provided an overview of GSK’s 2015 full year results and outlook for the future. The webcast of the event will be archived for 90 days.

• Leerink Partners 5th annual global healthcare conference transcript

12 January 2016

34th Annual JP Morgan Healthcare Conference, San Francisco USA

Andrew Witty, CEO, gave a presentation at the 34th Annual JP Morgan Healthcare Conference in San Francisco, providing an overview of progress the company has made during 2015.

• Andrew Witty JP Morgan presentation
• Andrew Witty JP Morgan transcription (PDF - 304.1KB)

18 December 2015

David Redfern

David Redfern, Chief Strategy Officer, discusses the two transactions with Bristol-Myers Squibb to acquire their late-stage HIV pipeline assets and also their pre-clinical and discovery stage research assets.

• ViiV-BMS investor transcript (PDF - 173.8KB)

03 November 2015

R&D event

On Tuesday 3 November, we hosted an event focusing on our R&D pipeline. This provided a unique insight into the innovative medicines and vaccines that GSK is developing for the future.

• R&D event full presentation (PDF - 4.3MB)
• R&D event full transcript (PDF - 528.4KB)
• R&D event Andrew Witty introduction presentation (PDF - 564.2KB)
• R&D event Andrew Witty introduction transcript (PDF - 37.7KB)
• Dr Patrick Vallance HIV, infectious diseases respiratory, PHI presentation (PDF - 1.6MB)
• Dr Patrick Vallance HIV, infectious diseases respiratory, PHI transcript (PDF - 238.2KB)
• Dr Patrick Vallance immuno-inflammation, Oncology, rare diseases presentation
• Dr Patrick Vallance immuno-inflammation, Oncology, rare diseases transcript
• Dr Moncef Slaoui vaccines business presentation (PDF - 736.7KB)
• Dr Moncef Slaoui vaccines business transcript (PDF - 101.3KB)

06 May 2015

Investor event

The Investor event outlined the Group’s strategy for 2015 and beyond including presentations from the heads of our Vaccines, Pharmaceuticals and Consumer businesses together with Sir Andrew Witty, Chief Executive Officer and Simon Dingemans, Chief Financial Officer.

• Simon Dingemans financial outlook presentation (PDF - 321.3KB)
• Simon Dingemans financial outlook transcript (PDF - 37.9KB)
• Investor event full presentation (PDF - 3.0MB)
• Investor event full transcript
• Andrew Witty strategic outlook presentation (PDF - 382.0KB)
• Andrew Witty strategic outlook transcript (PDF - 35.9KB)
• Dr Moncef Slaoui vaccine business presentation (PDF - 949.9KB)
• Dr Moncef Slaoui vaccine business transcript (PDF - 67.0KB)
• Abbas Hussain pharmaceuticals business presentation (PDF - 890.5KB)
• Abbas Hussain pharmaceuticals business transcript (PDF - 44.2KB)
• Emma Walmsley consumer healthcare presentation (PDF - 1.4MB)
• Emma Walmsley consumer healthcare transcript (PDF - 41.9KB)

13 January 2015

33rd Annual JP Morgan Healthcare Conference

David Redfern, Chief Strategy Officer, gave a presentation at the 33th Annual JP Morgan Healthcare Conference in San Francisco.

• 33rd Annual JP Morgan healthcare conference full presentation (PDF - 1.4MB)
• 33rd Annual JP Morgan healthcare conference full transcript (PDF - 1.4MB)

19 September 2014

Bank of America Merrill Lynch Global Healthcare Conference, London UK

Simon Dingemans, Chief Financial Officer, gave a presentation at the Bank of America Merrill Lynch Global Healthcare conference in London on 19th September 2014. Simon provided an overview of the recent results and the shape of the company going forward.

• Bank Of America healthcare conference (PDF - 683.3KB)

24 February 2014

Citi Global Healthcare Conference, New York USA

Andrew Witty, CEO, presented at the Citi Global Healthcare Conference on February 24, 2014 in New York. Andrew opened with a few minutes of brief remarks followed by a 'fireside chat' question and answer session.

Investor Event at ERS 2014, Munich

Darrell Baker, Senior Vice President, Head of Global Respiratory Franchise hosted an investor event comprising a presentation and Q&A session based on data presented at ERS.

• ERS investor briefing presentation
• ERS investor briefing transcript (PDF - 327.3KB)

14 January 2014

32nd Annual JP Morgan Healthcare Conference, San Francisco USA

Simon Dingemans, Chief Financial Officer, gave a presentation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco. Simon provided an overview of the progress being made in implementing the company’s strategy.

• JP Morgan healthcare conference 2014 transcript (PDF - 555.9KB)
• JP Morgan healthcare conference 2014 transcript (PDF - 83.6KB)
• JP Morgan healthcare conference 2014 transcript Q&A (PDF - 114.2KB)

06 December 2013

Leerink Swann PolarXpress, Philadelphia

Dr Paolo Paoletti, President of GSK Oncology, hosted an investor event organized by Leerink Swann at the GSK offices in Philadelphia.

• Leerink Swann polarxpress 2013 (PDF - 1.9MB)

22 August 2013

North Carolina CEO Forum

Deirdre Connelly, President, North America Pharmaceuticals, spoke at the North Carolina CEO Forum about the importance of curiosity, vision, flexibility, and risk-taking to create a high-performing, innovative, and sustainable business.

• North Carolina CEO forum speech 2013 (PDF - 74.0KB)

12 June 2013

Goldman Sachs 34th Annual Global Healthcare Conference, California USA

David Redfern, Chief Strategy Officer, gave a fireside chat on GSK’s business strategy and addressed questions in front of a large group of US investors at the Goldman Sachs Conference in California on Wednesday 12 June 2013.

21 May 2013

Investor Event at ATS 2013, Philadelphia

Darrell Baker, Senior Vice President, Head of Global Respiratory Franchise hosted an investor event comprising a short presentation and Q&A session based on data presented at ATS.

• ATS analyst and investor event 2013 (PDF - 998.9KB)

13 February 2013

Leerink Swann Healthcare Conference

Simon Dingemans, Chief Financial Officer, addressed questions in front of a large group of US investors at the Leerink Swann Global Healthcare Conference on Wednesday, February 13 in New York.  Simon provided an overview of GSK’s 2012 full year results and outlook for the future.

09 January 2013

Late-stage pipeline review - Patrick Vallance

Patrick Vallance, President, Pharmaceutical R&D gave a presentation at the 31st Annual JP Morgan Healthcare Conference in San Francisco. Patrick provided a review of the progress being made on the late stage pipeline.

• Late Stage Pipeline Review 2013 (PDF - 664.5KB)

04 December 2012

Late-stage pipeline review - Sir Andrew Witty, Dr Moncef Slaoui, and Dr Patrick Vallance

Sir Andrew Witty (CEO), Dr Moncef Slaoui (Chairman of R&D) and Dr Patrick Vallance (President of Pharmaceutical R&D) together with senior R&D leaders hosted a seminar focusing on GSK’s late stage pipeline. The event brought together the progress made in 2012, as Phase III programmes for a significant number of potential new drugs have concluded. It also provided an overview of our progress on our returns driven strategy in R&D and the sustainability of our pipeline.

• Late stage pipeline review (PDF - 2.1MB)

05 November 2012

Annual Pharmaceutical Regulatory and Compliance Congress

Deidre Connelly, President North America Pharmaceuticals, spoke at the 13th Annual Pharmaceutical Regulatory and Compliance Congress about how we conduct our business.

• GSK Deirdre Connelly PharmEHR summit speech 21 March 2012

01 October 2012

Investor Meeting at ESMO, Vienna

Dr Paolo Paoletti, President of GSK Oncology, hosted an investor event in conjunction with data presented at the European Society for Medical Oncology.

• ESMO analyst presentation 1 Oct 2012 (PDF - 573.3KB)

27 July 2012

Investor Meeting at IAC, Washington

ViiV Healthcare Chairman David Redfern, CEO Dominique Limet and Chief Scientific and Medical Officer, John Pottage, hosted an investor event at the International AIDS Conference (IAC).

• IAC analyst presentation (PDF - 471.5KB)

09 June 2012

Investor Meeting at ADA, Philadelphia

Dr Carlo Russo, Senior Vice President and Head of Albiglutide Development hosted an investor event in conjunction with data presented at the American Diabetes Association meeting.

• Ada Analyst Meeting 2012 (PDF - 290.3KB)

04 June 2012

Investor Meeting at ASCO, Chicago

Paolo Paoletti, President of GSK Oncology, hosted an investor event in conjunction with data presented at the American Society of Clinical Oncology (ASCO) meeting.

15 May 2012

World Affairs Council, Philadelphia

Deirdre Connelly, President, North America Pharmaceuticals, gave a speech at the World Affairs Council (WAC) in Philadelphia about how the challenges and opportunities facing the pharmaceutical business.

• Deirdre Connelly North America pharma, GSK World Affairs Council 15 May 2012 (PDF - 124.0KB)

29 March 2012

R&D Seminar

Moncef Slaoui, Chairman of Research & Development and Patrick Vallance, President, Pharmaceuticals R&D, presented a live webcast - Capital Allocation in R&D and a DPU Deep Dive.

• R&D Seminar (PDF - 2.6MB)

21 March 2012

PharmEHR Summit, Philadelphia

Deirdre Connelly, President, North America Pharmaceuticals, gave a speech at PharmEHR Summit in Philadelphia about how GSK sees healthcare evolving and how electronic health records fit into that shifting landscape.

• GSK Deirdre Connelly PharmEHR summit speech 21 March 2012 (PDF - 108.7KB)

10 January 2012

Annual JP Morgan Healthcare Conference

Simon Dingemans, Chief Financial Officer, gave a presentation at the 30th Annual JP Morgan Healthcare Conference in San Francisco.  Simon provided an overview of the progress being made in implementing GSK’s strategy.

• GSK - Simon Dingemans JP Morgan 10 Jan 2012 (PDF - 4.1MB)

01 December 2011

Core Earnings Reporting

Simon Dingemans, Chief Financial Officer discusses the methodology GSK will use for its core earnings reporting to begin with effect from Q1 2012.

• GSK core reporting announcement (PDF - 272.6KB)
• GSK core reporting presentation 1 Dec 2011 (PDF - 313.8KB)
• GSK core reporting historical restatements (XLS - 162.5KB)

14 November 2011

Credit Suisse Healthcare Conference, Hong Kong

Abbas Hussain, President, Emerging Markets & Asia Pacific gave a presentation at the Credit Suisse Asia Healthcare Conference in Hong Kong.  Abbas provided an overview of GSK's emerging markets strategy.

• Credit Suisse 2011 healthcare conference (PDF - 846.1KB)

05 May 2011

Bernstein Conference, New York

Adrian Rawcliffe, SVP Finance North American Pharmaceuticals, presented at the Bernstein Pharma Conference: “Pharmaceutical R&D Productivity: Diagnosing the Problem & Searching for Solutions” in New York City. The conference was attended by over 100 investors. Ad discussed GSK’s R&D Strategy and its Focus on Return on Investment.

• GSK's AD Rawcliffe presentation at bernstein pharma long view conference (PDF - 451.1KB)

23 March 2011

Citi’s Seminar in London on Vaccines in Emerging Markets

Martin Andrews, SVP – Global Vaccines Centre of Excellence, GSK Biologicals, gave a presentation on GSK’s vaccines business at Citi’s Seminar in London on Vaccines in Emerging Markets.

• Martin Andrews' presentation (PDF - 2.1MB)

17 March 2011

Andrew Witty presents to the US State Department

GSK CEO Andrew Witty presented at the United States Department of State symposium, “The Role of Innovation in Addressing Global Health”. In his address, which was convened to discuss advances and ways of working together to overcome diseases of the developing world, Andrew expanded upon GlaxoSmithKline’s commitments in this area.

• Summary of remarks made by GSK CEO the role of innovation in addressing global health (PDF - 165.1KB)

10 March 2011

Presentation to investors

Abbas Hussain, President, Emerging Markets, gave a presentation to a small group of investors, where he provided an overview of GSK's emerging markets strategy.

• Abbas Hussain emerging markets (PDF - 1.9MB)

08 March 2011

Cowen and Company 31st Annual Health Care Conference

Patrick Vallance, SVP – Medicines Discovery and Development, gave a presentation at the Cowen and Company 31st Annual Health Care Conference in Boston. Patrick provided an overview of GSK’s R&D Strategy and its Focus on Return on Investment.

• GSK's Patrick Vallance presentation at Cowen healthcare conference (PDF - 475.9KB)

21 February 2011

CED Biotech/Life Science Conference

Deirdre Connelly, President, North American Pharmaceuticals, addressed the CED Biotech/Life Science Conference in Raleigh, Durham, on 21 February 2011.

• Life science conference 2011 (PDF - 273.2KB)

10 February 2011

The Economist Pharma Summit

David Redfern, GSK Chief Strategy Officer, was one of the two keynote speakers at The Economist Pharma Summit Reinventing Pharma for a New Generation  on 10 February 2011 in London. He outlined GSK’s strategic priorities, our innovative approach to pricing and the value of our late stage pipeline coupled with our ongoing efforts to drive the effectiveness of R&D.

• David Redfern Economist pharma summit 10 February 2011 (PDF - 1.0MB)

24 January 2011

CBI 8th Annual Pharmaceutical Compliance Conference

Deirdre Connelly, President, North American Pharmaceuticals, addressed the 8th annual Center for Business Intelligence (CBI) pharmaceutical compliance conference on 24 January. Deirdre spoke about what the pharmaceutical industry must do to build trust.

• GSK Deirdre Connelly CBI annual Pharma compliance congress (PDF - 279.9KB)

12 January 2011

JP Morgan Healthcare Conference

David Redfern, Chief Strategy Officer at GlaxoSmithKline, gave a presentation at the 29th Annual JP Morgan Healthcare Conference in San Francisco.  David provided an overview of the progress being made in implementing GSK’s strategy.

• Jp Morgan 2011 Healthcare Conference (PDF - 4.5MB)

09 December 2010

CEO Andrew Witty discusses R&D and drug discovery on BBC Radio 4

CEO Andrew Witty discusses R&D and drug discovery on BBC Radio 4.

02 December 2010

Eddie Gray, President GSK Pharma Europe, speaks at FT pharmaceutical conference

The 27th annual FT Global Pharmaceutical & Biotechnology Conference took place in London on 1–2 December 2010. The event brought together thought-leaders from the pharmaceutical industry, patient groups, regulators, health technology assessment (HTA) groups to share insights and discuss the future for healthcare and the role of the pharmaceutical industry.

• GSK's Eddie Gray Speaks at FT pharmaceutical (PDF - 339.8KB)

01 December 2010

CLSA China Conference

Mark Reilly, GM, Pharmaceuticals China & Hong Kong, gave a presentation at the CLSA China Conference on December 1 in New York City. Mark gave an update on GSK’s strategy and progress in its pharmaceuticals business in China.

• CLSA emerging markets Mark Reilly (PDF - 461.1KB)

22 November 2010

CEO Andrew Witty featured in The World in 2011

In The World in 2011, published in November 2010 by The Economist, Andrew Witty, CEO of GlaxoSmithKline, calls on the pharmaceutical industry to do more with less—and still be innovative.

• GSK's Andrew Witty features in the Economist's the World In 2011 (PDF - 113.9KB)

19 November 2010

Mind the Medicine Gap

In this Open University programme on global access to medicines, Jon Pender of GlaxoSmithKline discusses the importance of intellectual property and why it is a critical mechanism to allow companies to generate funds for reinvestment to help create the medicines of the future.The programme also discusses how pharmaceutical companies can help to tackle neglected tropical diseases and improve access to medicines in developing nations.

• Mind the medicine map transcript (PDF - 39.2KB)

10 November 2010

Credit Suisse Healthcare Conference, Phoenix, AZ

Deirdre Connelly, President, North America Pharmaceuticals, gave a presentation at the 2011 Annual Credit Suisse Healthcare Conference in Phoenix, AZ on 10 November. The presentation was attended by institutional investors and portfolio managers. Deirdre provided an overview of GSK’s US Pharmaceuticals business.

• Deirdre Connelly's Credit Suisse presentation (PDF - 754.5KB)

Credit Suisse Healthcare Conference

Andrew Witty, Chief Executive Officer, gave a presentation at the 2010 Annual Credit Suisse Health Care Conference in Phoenix, AZ. The presentation was attended by over 100 institutional investors and portfolio managers. Andrew provided an overview of the progress being made in implementing the company's strategy.

• Andrew Witty, CEO, GSK presentation at Credit Suisse - Nov 2010 (PDF - 754.5KB)

22 September 2010

Sanford C. Bernstein Pan-European Strategic Decisions Conference

Julian Heslop (CFO) gave a presentation at the Sanford C. Bernstein 7th Pan-European Strategic Decisions Conference in London.  Julian provided an overview of GSK’s Half Year 2010 results and an outlook for the future.

• Cowen healthcare conference Julian Heslp CFP (PDF - 1.5MB)

17 September 2010

Bank of America/Merrill Lynch Global Healthcare Conference

Julian Heslop (CFO) gave a presentation at the BoA/Merrill Lynch Healthcare Conference in London.  Julian provided an overview of GSK’s Half Year 2010 results and an outlook for the future.

• Merrill Lynch conference Julian Heslp CFO (PDF - 1.8MB)

23 June 2010

Investor Meeting with John Clarke, President, Worldwide Consumer Healthcare

John Clarke (President, Worldwide Consumer Healthcare), along with senior members of his management team, presented on GSK's Consumer Healthcare business.

• Investor meetings 2010 (PDF - 2.5MB)

21 June 2010

Investor Visit to GSK Biologicals, Wavre, Belgiu

Dr Thomas Breuer (Senior Vice President, Head of Global Development, GSK Biologicals) presented on GSK’s vaccines business.

• Dr Thomas Breuer's presentation (PDF - 2.3MB)
• Martin Andrews presentation (PDF - 3.1MB)
• Vincent Bruchard's presentation (PDF - 1.6MB)

16 June 2010

Goldman Sachs Thirty-First Annual Health Care Conference in California

Andrew Witty gave the keynote speech regarding the Pharmaceutical Industry and GSK's strategy at the Goldman Sachs Thirty-First Annual Health Care Conference in California.

01 June 2010

Slides Presented at Investor Meetings in June

This is a general slide deck presented at investor meetings during June 2010.

26 May 2010

2010 Citi Investment Research Global Health Care Conference in New York

Simon Harford (SVP, Finance, Emerging Markets) participated on a panel at the 2010 Citi Investment Research Global Health Care Conference in New York. The panel was entitled "The Opportunities and Challenges of Emerging Markets for Health Care"

• Simon Harford GSK emerging markets (PDF - 579.5KB)

12 January 2010

JP Morgan 28th Annual Healthcare Conference

Andrew Witty (CEO) gave a presentation to investors at the JP Morgan 28th Annual Healthcare Conference in San Francisco. Andrew provided an overview of the progress being made in implementing the company's strategy.

• 28th Annual healthcare conference JP Morgan (PDF - 1.6MB)

• International edition
• Australia edition
• Europe edition

GSK drugmaker sets ambitious sales target before shake-up

Firm aims to boost pharmaceutical and vaccine business by 5% annually for five years

GSK has cut its dividend and set ambitious sales targets as its under-pressure chief executive, Dame Emma Walmsley, pledged to lead Britain’s second-biggest drugmaker through a corporate shake-up next year.

GSK is spinning off its consumer healthcare business and aims to increase sales at the remaining pharmaceuticals and vaccines business, provisionally called “New GSK”, by 5% annually over the next five years, while profits are projected to grow by 10% a year.

It intends to raise sales at New GSK to £33bn by 2031, which is almost as much as the £34bn achieved by the whole group, including consumer health, last year.

Investors were braced for a steep dividend cut, from 80p a share this year, but will receive a better-than-expected 55p a share in total dividends next year from GSK and the new consumer business. The dividend for New GSK will start at 45p in 2023.

Money saved by the dividend cut will be invested in research and development to strengthen the firm’s pipeline of new drugs.

The targets and dividend change were set out in a four-hour live video presentation to investors and analysts on Wednesday against a backdrop of speculation over Walmsley’s future.

The New York hedge fund Elliott Management, which took a sizeable stake in GSK in April to push for change , has reportedly questioned whether Walmsley is the right person to lead New GSK.

Speaking on Wednesday before the meeting , Walmsley said:“Let me tell you what I am. I am a change agent, I am a business leader, and I am very excited about the new plans for a new GSK that we are laying out today. I have been leading and driving very hard a shift to a more performance-oriented company … My focus is resolutely on leading us through this transformation, through a successful separation and with momentum beyond that.”

GSK is demerging at least 80% of its stake in the consumer healthcare venture in mid-2022, with the rest to be sold off when market conditions allow.

Walmsley said this was set up to be “very, very shareholder-friendly”. Existing GSK shareholders would receive shares in the new consumer company, with brands such as Panadol, Sensodyne and Voltaren, which will be listed in London and New York. Some analysts had advocated an initial public listing to raise money.

Walmsley highlighted the achievements made since she inherited a threadbare drug pipeline four years ago, including a 30%-plus boost in R&D spending, producing a suite of 20 vaccines and 42 medicines.

“I’m very aware that GSK shares have underperformed for a long period,” she said. “The transformation achieved over the last four years creates a completely different platform for growth and significant shareholder value.”

She told investors: “This is a company that has perennially disappointed,” adding that GSK was set up for “a step change in performance versus our history and a commitment to competitive growth”.

The GSK share price ended the day up 1% at £14.09.

Mike Fox, a senior fund manager at Royal London Asset Management, a GSK shareholder, said: “This updated strategy moves the needle at GlaxoSmithKline , from a focus on restructuring to a story driven by growth. The targets show that management are prepared to be accountable for this growth, driving an improved shareholder experience, and we look forward to working with them to deliver it.”

The company is aiming for high-single-digit percentage growth in vaccines and double-digit growth for specialist medicines over the next five years.

Peter Welford, an analyst at Jefferies, said the group needed “to build belief in the pipeline”. The firm focuses on cancer, immunology, respiratory drugs and infectious diseases, as well as vaccines.

GSK has also developed a long-acting, injectable HIV drug, the main ingredient of which can also be used to prevent HIV infection. Known for its shingles, cervical cancer and flu vaccines, it is also developing vaccines for meningitis and RSV (respiratory syncytial virus) , a common virus that can lead to hospital admission for older adults. It estimates that the RSV vaccine market for older adults is worth £5bn a year.

• GlaxoSmithKline
• Pharmaceuticals industry
• Healthcare industry
• Hedge funds
• Financial sector

Most viewed

• Skip to Content
• Skip to Search

May 03 2023

For media and investors only

US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

• Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
• The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease
• US launch is planned before the 2023/24 RSV season

Issued: Philadelphia

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older adults to be approved anywhere in the world.

Tony Wood, Chief Scientific Officer, GSK, said: “Today marks a turning point in our effort to reduce the significant burden of RSV. AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”

RSV is a common, contagious virus that can lead to potentially serious respiratory illness. It causes approximately 177,000 hospitalizations and an estimated 14,000 deaths in the US in adults aged 65 years and older each year. 1,2,3 Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness and drive the majority of RSV hospitalizations. 4

John Kennedy, MD, President, American Medical Group Association (AMGA), added: “For decades, AMGA and the healthcare community at large have been active in finding ways to increase adult immunizations. As a result, we are pleased that we can now add a respiratory syncytial virus vaccine to providers’ options for patient care. With this vaccine, Americans over the age of 60, and particularly those with underlying health conditions like COPD, asthma, or congestive heart failure, will have a vaccine to help protect against potentially serious outcomes from RSV.”

The US FDA approval is based on GSK’s landmark positive pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial data. In the trial, the vaccine showed statistically significant and clinically meaningful overall efficacy of 82.6% (96.95% CI, 57.9–94.1, 7 of 12,466 vs 40 of 12,494) against RSV-LRTD in adults aged 60 years and older, meeting the primary endpoint. In addition, efficacy was 94.6% (95% CI, 65.9–99.9, 1 of 4,937 vs 18 of 4,861) in older adults with at least one underlying medical condition of interest, such as certain cardiorespiratory and endocrine-metabolic conditions. Efficacy against severe RSV-LRTD, defined as an RSV-associated LRTD episode preventing normal, everyday activities, was 94.1% (95% CI, 62.4–99.9, 1 of 12,466 vs 17 of 12,494).

The vaccine was generally well tolerated with an acceptable safety profile. The most frequently observed solicited adverse events were injection site pain, fatigue, myalgia, headache, and arthralgia. These were generally mild to moderate and transient.

In June 2023, the Advisory Committee on Immunization Practices (ACIP) will make recommendations on the appropriate use of the vaccine in the US. The vaccine will be available for older adults before the 2023/24 RSV season, which typically starts ahead of the winter months.

In April 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the vaccine for the prevention of LRTD caused by RSV in adults aged 60 years and older. A final European regulatory decision is anticipated in the coming months, while regulatory reviews are ongoing in Japan and several other countries.

About AREXVY (respiratory syncytial virus vaccine, adjuvanted)

Respiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01 E adjuvant.

In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older. GSK’s RSV older adult vaccine is not currently approved anywhere outside the US. The proposed trade name remains subject to regulatory approval outside the US.

A clinical trial that aims to expand the population who may benefit from RSV vaccination into adults aged 50-59, including participants with underlying comorbidities, is fully recruited. Results are expected in 2023, together with additional results from the AReSVi-006 phase III efficacy trial and the AReSVi-004 immunogenicity trial. These trials continue to evaluate an annual revaccination schedule and protection/immunogenicity over multiple seasons following one dose of the RSV vaccine. Results from two additional influenza vaccine co-administration trials are also expected before the June 2023 Advisory Committee on Immunization Practices (ACIP) meeting.

The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc.

Please see the full US Prescribing Information: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PDF

Important Safety Information for AREXVY

The following is based on the US Prescribing Information for AREXVY. Please consult the full Prescribing Information for all the labelled safety information.

• Do not administer AREXVY to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of AREXVY.
• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY.
• Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting.
• Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY.
• The most commonly reported (≥10%) adverse reactions were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%).
• Vaccination with AREXVY may not result in protection of all vaccine recipients.

About RSV in older adults

RSV is a common contagious virus affecting the lungs and breathing passages. Older adults are at high risk for severe disease due in part to age-related decline in immunity, and older adults with underlying conditions are at even greater risk for severe disease. RSV can exacerbate conditions, including chronic obstructive pulmonary disease (COPD), asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalization, and death. Each year, approximately 177,000 adults 65 years and older are hospitalized in the US due to RSV; an estimated 14,000 cases result in death. 3 For adults 60 and older, data suggest an increased risk for severe RSV infection that can lead to hospitalization. 5 , 6 Adults with underlying conditions are more likely to seek medical services and have higher hospitalization rates than adults without these conditions.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company .

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include but are not limited to those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, GSK’s Q1 Results for 2023 and any impacts of the COVID-19 pandemic.

References 

• Centers for Disease Control and Prevention. RSV Transmission. Accessed March 2023. Available at: https://www.cdc.gov/rsv/about/transmission.html
• National Foundation for Infectious Diseases. Respiratory Syncytial Virus in Older Adults: A Hidden Annual Epidemic. 2016. www.nfid.org/wp-content/uploads/2019/08/rsv-report.pdf. Accessed March 2023. 
• Falsey AR, et al. N Engl J Med 2005; 352:1749-1759 DOI: 10.1056/NEJMoa043951. Accessed March 2023.
• Centers for Disease Control and Prevention. RSV in Older Adults and Adults with Chronic Medical Conditions. Accessed March 2023. Available at: www.cdc.gov/rsv/high-risk/older-adults.html
• Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222(8):1298-1310. doi:10.1093/infdis/jiaa361.
• Belongia EA, King JP, Kieke BA, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018;5(12):ofy316. doi:10.1093/ofid/ofy316.

You may also like

Press releases

Keep up to date with our news and recent announcements

Media contacts

Contact our GSK US Media Team. We are committed to responding to the information needs of the media as quickly as possible

We unite science, technology and talent to get ahead of disease together

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

News & Insights

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

November 01, 2023 — 11:21 am EDT

Written by Zacks Equity Research for Zacks  ->

GSK plc GSK reported adjusted earnings of $1.26 per American depositary share (“ADS”) in third-quarter 2023, beating the Zacks Consensus Estimate of $1.09. Adjusted earnings rose 7% year over year on a reported basis and 17% at a constant exchange rate (CER).

Quarterly revenues rose 4% on a reported basis and 10% on a CER basis to $10.3 billion (£8.1 billion), beating the Zacks Consensus Estimate of $9.7 billion. This upside can be attributed to the rising HIV and Vaccine sales, which partially offset the declining COVID-19 product sales.

GSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines.

In the year so far, shares of GSK gained 1.6% against the industry ’s 24.6% fall.

Segment Discussion

Sales in the Specialty Medicines segment fell 1% at CER due to the declining Xevudy sales. Excluding Xevudy sales, revenues from the Specialty Medicines segment were up 17% at CER. Sales growth of HIV and respiratory drugs was also strong.

GSK did not record any Xevudy sales during the third quarter, in line with second-quarter 2023 levels. GSK markets Xevudy in collaboration with Vir Biotechnology VIR . Last year, the FDA withdrew the emergency use authorization (EUA) granted to GSK/Vir Biotechnology’s Xevudy. The withdrawal decision for the Vir Biotechnology-partnered antibody therapy was based on data that showed that it was unlikely for the Xevudy dose to be effective against the Omicron variant.

HIV sales increased 15% at CER, driven by sales growth of new HIV drugs — Juluca, Dovato, Cabenuva, Rukobia and Apretude. GSK markets Juluca in collaboration with J&J JNJ .

GSK generates the majority of its HIV sales from its dolutegravir franchise, comprising three-drug regimens — Triumeq and Tivicay — and two-drug regimens — Dovato and J&J-partnered Juluca. The launch of the two-drug regimens has been eroding sales and market share of the three-drug regimens following their launch. During the third quarter, GSK and J&J’s Juluca and Dovato contributed almost 40% to total HIV sales.

While sales of the dolutegravir franchise were up 5% at CER in the U.S. market, they were flat in Europe. In International markets, sales were up 47% at CER.

Sales of Triumeq declined 16% at CER, while Tivicay sales rose 7%.

Sales of the immuno-inflammation drug Benlysta were up 20% in the quarter, reflecting growth across all regions.

Sales of the respiratory drug Nucala were up 19% at CER during the quarter, driven by growth across all regions, especially in the U.S. market.

Oncology sales were up 26% year over year, driven by strong growth in Jemperli and Zejula sales. The growth was partially offset by Blenrep sales, which fell 69% during the quarter following thedrug’s withdrawal from the U.S. market last November.

Sales of Zejula rose 22% at CER in the quarter. Jemperli added £45 million to the top line in the third quarter compared to £25 million in second-quarter 2023. The uptick was driven by new patient starts in the United States.

The recently launched blood cancer drug Ojjaara, generated £4 million in product sales in the first quarter of its commercial launch. The FDA approved the drug in September for treating myelofibrosis patients with anaemia.

Sales of General Medicines were down 2% at CER during the quarter. This downside was due to the impact of Returns and Rebates (“RAR”) adjustments in the US market, partially offset by solid sales growth of respiratory drugs, Anoro Ellipta and Trelegy Ellipta, and the post-pandemic recovery of Augmentin and Avodart sales.

Trelegy Ellipta sales surged 23% year over year, owing to strong growth in all regions. Sales of Anoro Ellipta were up 15% at CER during the third quarter. Key established drug Advair/Seretide sales were down 14% year over year. Sales on Revlar/Breo Ellipta were down 18% at CER year over year.

Vaccine Sales Rise

GSK’s third-quarter vaccine sales increased 33% at CER, driven by the successful launch of the RSV vaccine Arexvy in the United States and strong uptake for the Shingrix vaccine in ex-U.S. markets. GSK also recorded sales of £1 million from the COVID-19 booster vaccine co-developed in partnership with Sanofi, all of which were generated from outside the United States.

The first approved RSV vaccine for older adults, Arexvy, was commercially launched in Q3 and generated £709 million in sales, driven by strong demand and initial channel inventory build.Per management, Arexvy achieved two-thirds of the share of retail vaccinations in the quarter.

Shingrix sales rose 15% at CER during the quarter, driven by strong private uptake and public funding expansion in ex-U.S. markets.

In Meningitis vaccines, Bexsero sales were flat, while sales of Menveo rose 10%. Sales of the influenza vaccine, Fluarix, were down 4% at CER. Sales of Established vaccines were up 3% year over year.

Operating Expenses

Adjusted selling, general and administration (SG&A) costs increased 17% year over year at CER to £2.19 billion. The upside in SG&A costs was due to the launch of products in the Specialty Medicines and Vaccines segments.

Research and development (R&D) expenses rose 14% year over year at CER to £1.43 billion due to continued investment by management for pipeline advancement.

Raises 2023 Guidance

GSK raised its guidance for 2023. The company now expects sales to increase 12-13% in 2023 compared with the previously issued guidance of 8-10%. The uptick can be attributed to the strong growth momentum observed across all business segments, fueled by the launch of Arexvy in Q3. GSK expects Arexvy sales for the full year 2023 to be between £0.9 to £1.0 billion.

Management expects vaccine sales to increase around 20% at CER in 2023 (previously mid-teens percentage growth was anticipated), while sales of specialty medicines are now expected to increase in low double-digit percent at CER (previously high single-digit percentage). Management also expects low to mid-single-digit percent growth in the General Medicines segment’s turnover, which was previously expected to grow at a low single-digit percentage.

GSK expects adjusted operating profit growth to increase between 13% to 15% at CER (previously: 11% to 13%). The company also raised the guidance for its adjusted EPS, which is anticipated to grow in the range of 17-20%, a three-percentage point rise from the previously issued guidance of 14-17%.

The above guidance excludes any revenues from its COVID-related products. GSK does not expect significant COVID-19-related sales in 2023. If management were to add COVID sales, it expects a reduction of approximately 8% in turnover growth and a decline in adjusted operating profit growth by 4-5%.

GSK’s Q3 results were better than expected, as it beat estimates on both counts. This is the second time that GSK has raised its financial outlook this year, following the strong commercial launch for Arexvy in the United States. The company’s oncology portfolio, which has been facing a steep decline due to lower Blenrep sales in recent quarters, has started showing recovery on the back of rising Jemperli sales and newly launched Ojjaara.

These results are likely to reinvigorate investor confidence in the company’s pharmaceutical business following the spin-off of its consumer business into Haleon.

GSK PLC Sponsored ADR Price

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report

Vir Biotechnology, Inc. (VIR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks mentioned

More related articles.

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

To add symbols:

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
• Copy and paste multiple symbols separated by spaces.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .

For inquiries related to this message please contact our support team and provide the reference ID below.

• SUGGESTED TOPICS
• The Magazine
• Newsletters
• Managing Yourself
• Managing Teams
• Work-life Balance
• The Big Idea
• Data & Visuals
• Reading Lists
• Case Selections
• HBR Learning
• Topic Feeds
• Account Settings
• Email Preferences

How to Present to an Audience That Knows More Than You

• Deborah Grayson Riegel

Lean into being a facilitator — not an expert.

What happens when you have to give a presentation to an audience that might have some professionals who have more expertise on the topic than you do? While it can be intimidating, it can also be an opportunity to leverage their deep and diverse expertise in service of the group’s learning. And it’s an opportunity to exercise some intellectual humility, which includes having respect for other viewpoints, not being intellectually overconfident, separating your ego from your intellect, and being willing to revise your own viewpoint — especially in the face of new information. This article offers several tips for how you might approach a roomful of experts, including how to invite them into the discussion without allowing them to completely take over, as well as how to pivot on the proposed topic when necessary.

I was five years into my executive coaching practice when I was invited to lead a workshop on “Coaching Skills for Human Resource Leaders” at a global conference. As the room filled up with participants, I identified a few colleagues who had already been coaching professionally for more than a decade. I felt self-doubt start to kick in: Why were they even here? What did they come to learn? Why do they want to hear from me?

• Deborah Grayson Riegel is a professional speaker and facilitator, as well as a communication and presentation skills coach. She teaches leadership communication at Duke University’s Fuqua School of Business and has taught for Wharton Business School, Columbia Business School’s Women in Leadership Program, and Peking University’s International MBA Program. She is the author of Overcoming Overthinking: 36 Ways to Tame Anxiety for Work, School, and Life and the best-selling Go To Help: 31 Strategies to Offer, Ask for, and Accept Help .

Partner Center

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Premium News
• Biden Economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Personal Loans
• Student Loans
• Car Insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Gsk plc (lon:gsk) stock goes ex-dividend in just four days.

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is important as the process of settlement involves two full business days. So if you miss that date, you would not show up on the company's books on the record date. Therefore, if you purchase GSK's shares on or after the 16th of May, you won't be eligible to receive the dividend, when it is paid on the 11th of July.

The company's next dividend payment will be UK£0.15 per share, on the back of last year when the company paid a total of UK£0.58 to shareholders. Based on the last year's worth of payments, GSK has a trailing yield of 3.2% on the current stock price of UK£17.995. If you buy this business for its dividend, you should have an idea of whether GSK's dividend is reliable and sustainable. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

View our latest analysis for GSK

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. GSK is paying out an acceptable 53% of its profit, a common payout level among most companies. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Fortunately, it paid out only 42% of its free cash flow in the past year.

It's positive to see that GSK's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

Have Earnings And Dividends Been Growing?

Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. This is why it's a relief to see GSK earnings per share are up 3.6% per annum over the last five years. Earnings growth has been slim and the company is paying out more than half of its earnings. While there is some room to both increase the payout ratio and reinvest in the business, generally the higher a payout ratio goes, the lower a company's prospects for future growth.

The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. GSK has seen its dividend decline 5.1% per annum on average over the past 10 years, which is not great to see. It's unusual to see earnings per share increasing at the same time as dividends per share have been in decline. We'd hope it's because the company is reinvesting heavily in its business, but it could also suggest business is lumpy.

The Bottom Line

Is GSK worth buying for its dividend? While earnings per share growth has been modest, GSK's dividend payouts are around an average level; without a sharp change in earnings we feel that the dividend is likely somewhat sustainable. Pleasingly the company paid out a conservatively low percentage of its free cash flow. While it does have some good things going for it, we're a bit ambivalent and it would take more to convince us of GSK's dividend merits.

In light of that, while GSK has an appealing dividend, it's worth knowing the risks involved with this stock. In terms of investment risks, we've identified 3 warning signs with GSK and understanding them should be part of your investment process.

A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Follow Puck Worlds online:

• Follow Puck Worlds on Twitter

Site search

Filed under:

• Kontinental Hockey League

Gagarin Cup Preview: Atlant vs. Salavat Yulaev

Share this story.

• Share this on Facebook
• Share this on Twitter
• Share this on Reddit
• Share All sharing options

Share All sharing options for: Gagarin Cup Preview: Atlant vs. Salavat Yulaev

Gagarin cup (khl) finals:  atlant moscow oblast vs. salavat yulaev ufa.

Much like the Elitserien Finals, we have a bit of an offense vs. defense match-up in this league Final.  While Ufa let their star top line of Alexander Radulov, Patrick Thoresen and Igor Grigorenko loose on the KHL's Western Conference, Mytischi played a more conservative style, relying on veterans such as former NHLers Jan Bulis, Oleg Petrov, and Jaroslav Obsut.  Just reaching the Finals is a testament to Atlant's disciplined style of play, as they had to knock off much more high profile teams from Yaroslavl and St. Petersburg to do so.  But while they did finish 8th in the league in points, they haven't seen the likes of Ufa, who finished 2nd. 

This series will be a challenge for the underdog, because unlike some of the other KHL teams, Ufa's top players are generally younger and in their prime.  Only Proshkin amongst regular blueliners is over 30, with the work being shared by Kirill Koltsov (28), Andrei Kuteikin (26), Miroslav Blatak (28), Maxim Kondratiev (28) and Dmitri Kalinin (30).  Oleg Tverdovsky hasn't played a lot in the playoffs to date.  Up front, while led by a fairly young top line (24-27), Ufa does have a lot of veterans in support roles:  Vyacheslav Kozlov , Viktor Kozlov , Vladimir Antipov, Sergei Zinovyev and Petr Schastlivy are all over 30.  In fact, the names of all their forwards are familiar to international and NHL fans:  Robert Nilsson , Alexander Svitov, Oleg Saprykin and Jakub Klepis round out the group, all former NHL players.

For Atlant, their veteran roster, with only one of their top six D under the age of 30 (and no top forwards under 30, either), this might be their one shot at a championship.  The team has never won either a Russian Superleague title or the Gagarin Cup, and for players like former NHLer Oleg Petrov, this is probably the last shot at the KHL's top prize.  The team got three extra days rest by winning their Conference Final in six games, and they probably needed to use it.  Atlant does have younger regulars on their roster, but they generally only play a few shifts per game, if that. 

The low event style of game for Atlant probably suits them well, but I don't know how they can manage to keep up against Ufa's speed, skill, and depth.  There is no advantage to be seen in goal, with Erik Ersberg and Konstantin Barulin posting almost identical numbers, and even in terms of recent playoff experience Ufa has them beat.  Luckily for Atlant, Ufa isn't that far away from the Moscow region, so travel shouldn't play a major role. 

I'm predicting that Ufa, winners of the last Superleague title back in 2008, will become the second team to win the Gagarin Cup, and will prevail in five games.  They have a seriously well built team that would honestly compete in the NHL.  They represent the potential of the league, while Atlant represents closer to the reality, as a team full of players who played themselves out of the NHL. 

• Atlant @ Ufa, Friday Apr 8 (3:00 PM CET/10:00 PM EST)
• Atlant @ Ufa, Sunday Apr 10 (1:00 PM CET/8:00 AM EST)
• Ufa @ Atlant, Tuesday Apr 12 (5:30 PM CET/12:30 PM EST)
• Ufa @ Atlant, Thursday Apr 14 (5:30 PM CET/12:30 PM EST)

Games 5-7 are as yet unscheduled, but every second day is the KHL standard, so expect Game 5 to be on Saturday, like an early start. 

Loading comments...

• SI SWIMSUIT
• SI SPORTSBOOK
• MOUNTAIN WEST

Army Football Show Off New Championship Rings After CIC Trophy Presentation

Joe londergan | may 7, 2024.

• Army West Point Black Knights

This week, the Army Black Knights football team were officially presented the Commander-In-Chief's Trophy by President Biden. The trophy is given annually to the service academy football program that wins the three-team series between Army, Navy, and Air Force.

As part of the celebration, West Point also revealed the design for the rings that Army players will receive to commemorate the win.

💍 2023 CIC 🏆 CHAMPS 💍 pic.twitter.com/23nEi3ErlA — Army Football (@ArmyWP_Football) May 7, 2024

RELATED: Southern Miss HC Will Hall Talks What Buffalo Bills Are Getting In Frank Gore Jr.

The rings will feature a plethora of details with nods to the accomplishments of Army's senior class, as well as other classes who claimed the CIC trophy for West Point. This includes the ten seasons that Army has won the CIC trophy outright along the outer sides of the ring. The six stars on one side also symbolize the wins of the Army senior class over Navy and Air Force over the last few years.

Army's 2023 win was the first time that the Black Knights won the trophy outright since 2020.

Army football will open up the 2024 season on August 30 when they host FCS foe Lehigh. The Black Knights will face Air Force on November 2 and Navy on December 14.

JOE LONDERGAN

Joe covers college sports from the Group of Five ranks and beyond. He has worked in the sports industry since 2008, earned a bachelor's degree from the University of Louisville, and a Master's degree from Seattle University.

Follow joehio_

• Share full article

Advertisement

Supported by

‘Presentation is Everything’: Inside the World of Art Fair Booth Design

For gallery directors, including those at TEFAF New York, no detail is too trivial, and every millimeter matters.

By Liz Robbins

Before 89 international art dealers showcase their exquisite wares inside a building that was once the playground for New York’s rich and famous, they get the chance to be children again.

Their grown-up game? Designing strikingly unique booths out of tight uniform spaces for TEFAF New York, the European Fine Art Foundation fair at the Park Avenue Armory .

Some dealers still play with foam core models that resemble dollhouses. Others — those blessed with warehouse space — can create life-size replicas before shipping the pieces. Most in this digital age, however, tinker collaboratively inside 3-D digital structures as if they are playing video games.

Welcome to the passionately precise world of art fair design, where for gallery directors, no detail is too trivial, and every millimeter matters.

“Designing booths is one of my favorite things to do,” Evan Snyderman, a co-founder of R & Company gallery in New York, said gleefully. “It’s always been something I’ve done and to the point of almost driving my wife crazy because I’m constantly rearranging the house, moving things like one inch to the left.”

The son of Philadelphia gallery owners, Snyderman said he was already arranging his Matchbox cars in diagonal rows at 8 years old. He also placed his hand puppets on wall-mounted boxes and ordered his collection of daggers and pocketknives just so.

Now, he and his partners do it for a living.

“Like we learn in art school, presentation is everything,” said R & Company’s co-founder Zesty Meyers.

If nothing else, dealers take on TEFAF New York booths as a personal challenge.

“Honestly,” said the eponymous owner of Sean Kelly Gallery , “we all do more than enough art fairs and so one of the things that we’re always looking for is a way to kind of amuse ourselves and keep it fresh.”

About three months before the May fair, TEFAF officials email dealers booth and room assignments, and a menu of design options. Galleries choose the fabric color to cover the walls of the booths that sit under the cavernous ceiling. They also choose types of flooring, paint, electrical outlets, track lighting and temporary office furniture like storage cabinets.

The booths in the armory’s drill hall range in size from 20 square meters to 49 square meters (about 215 square feet to 527 square feet; TEFAF only provides metric measurements to its dealers). The period rooms, including three downstairs and 12 upstairs, range from about 355 to 656 square feet.

Galleries are strictly forbidden to do anything to alter these rooms that were once clubhouses for the companies belonging to the Seventh Regiment of the Armory on Park Avenue.

R & Company, which showcases historical and contemporary design, had always been tucked into the same back left corner of the drill hall until this year, when it moved upstairs. At first, Snyderman wanted to lighten the dark mahogany room equipped with 19th-century swords, shields and iron chandeliers.

Plans to hang a Katie Stout chandelier were rejected because it weighed more than 100 pounds. Although Snyderman decided to keep the interior of the room visible, he built a free-standing trellis for track lighting.

Snyderman worked twice a week together with his architect in computer sessions, starting with an anchor piece at the back of the room: a rare nearly seven-foot-tall Wendell Castle stack-laminated oak cabinet.

To draw viewers’ eyes to it, the pair created a 12-foot wall that partly blocked the windows behind it and would serve as a stage. They chose to paint it “quetzal,” a rich aqua color that serves as a uniting element for the room’s other pedestals. In their model, they incorporated Castle’s models for the sculpture, which will also be on display.

“That’s a big part of the design for us, the storytelling,” Snyderman said. He and his team went through at least six iterations of design layouts to place the other pieces in visual harmony, including a tomato red Lina Bo Bardi “Bowl Chair,” vessels by Roberto Lugo , and an Isamu Noguchi table, stool and lamp.

Kasmin Gallery , also in an upstairs period room, chose for its anchor piece Alma Allen ’s 190-pound bronze moth. That needed to be reinforced onto one of the temporary walls — painted dark gray — that the dealers built inside the existing walls.

During a visit in April to the gallery in Chelsea, a smaller version of the moth was already affixed diagonally to the foam core walls of the scale model, 31 inches by 16.5 inches by 14 inches. Edith Dicconson, a co-executive director of the gallery, delighted in trying different arrangements for a Robert Motherwell painting (reduced in scale to the size of a postage stamp) and a 3-D Max Ernst sculpture.

“We come in here and all of our heads can look in like this and collaborate,” she said, adding with a kidlike cackle, “Isn’t it fun?”

Kasmin’s goal is to create an elegant but accessible space, where the works of artists who were friends and collectors of each other’s work — like William N. Copley and Les Lalanne — can be in dialogue.

What might they be whispering?

“I think they would have conversations about the style in which they would work,” said Mariska Nietzman, a Kasmin co-executive director. “But I think they also would perhaps just have cups of coffee and glasses of wine.”

Boris Vervoordt of Axel Vervoordt gallery was much more serious in discussing his digitally rendered booth, which allowed his staff across multiple time zones to try different combinations during video calls.

His gallery has occupied the same upstairs period room at the fair for about four years, in part because TEFAF respects his zero-waste policy. Recycling the same structure makes it easier to substitute new works of art, like a rarely shown 1993 painting by Kazuo Shiraga in this year’s booth.

Instead of the same space, Andrew Duncanson of Modernity gallery in Stockholm, which specializes in 20th-century Nordic furniture, lighting and jewelry, chose to move from last year’s upstairs quiet period room to the crowded drill hall.

This year, he built a mock-up of the booth in his warehouse, featuring a Carl Malmsten daybed and a showstopper of a chandelier, “ Snowflake ” by Paavo Tynell.

“We want to create an ambience in the room where it feels like you can move right in,” he said.

Duncanson created that atmosphere so well last year that TEFAF New York’s director, Leanne Jagtiani, said she warned him, “ Don’t be surprised if you come in one morning and I’m here because I stayed overnight.”

Duncanson said that last year, TEFAF committee members told him his room design earned him an A+, even though Jagtiani said the design commendations were given in verbal rather than report card form.

For dealers, the sales ledgers are what ultimately matter.

This year, Sean Kelly will also set up in the drill hall, moving into a larger, back corner spot. It came, however, with a caveat: an immovable diagonal support wall. So Kelly and his crew made it into a room divider for three distinct views and a funnel for foot traffic.

At one entrance, a cast iron statue by Antony Gormley welcomes visitors. The anchor pieces will be any one of three large-scale works by the German photographer Candida Höfer and two paintings by the British artist Idris Khan .

A month before TEFAF, Terrill Warrenburg, art fair and special project manager at Sean Kelly Gallery, was still swapping options on the computer to see how their shapes, colors and themes interacted with one another. They also had to account for the possibility that a work could sell right before TEFAF opens, taking it off the roster.

“It is a bit like four-dimensional chess because you have all these options and you build around them and they have to play nicely together — and you keep going until you feel like you got something that clicks,” Kelly said.

He laughed, adding, “And then, inevitably, you get there and then you change it all around.”

Art and Museums in New York City

A guide to the shows, exhibitions and artists shaping the city’s cultural landscape..

At the Metropolitan Museum of Art’s Costume Institute, the immersive “Sleeping Beauties: Reawakening Fashion” exhibition features fragile dresses inside airtight vitrines, overcoats growing grass and pat-’n-sniff walls. But does it work ?

The Kosovar artist Petrit Halilaj  began drawing as a child in the Balkans during a violent decade. His world of childhood innocence and adult experience comes to the roof of the Met .

As his bullet-riddled panels go up at Gagosian, Maurizio Cattelan, in a rare in-person interview, tells why he turned his sardonic gaze on a violence-filled world .

In his biggest exhibit since a 2013 retrospective at the Guggenheim, Christopher Wool has created his own show in an uninhabited office in Manhattan’s Financial District .

Looking for more art in the city? Here are the gallery shows not to miss in May .

• Yekaterinburg
• Novosibirsk
• Vladivostok

• Tours to Russia
• Practicalities
• Russia in Lists

Rusmania • Deep into Russia

Out of the Centre

Savvino-storozhevsky monastery and museum.

Zvenigorod's most famous sight is the Savvino-Storozhevsky Monastery, which was founded in 1398 by the monk Savva from the Troitse-Sergieva Lavra, at the invitation and with the support of Prince Yury Dmitrievich of Zvenigorod. Savva was later canonised as St Sabbas (Savva) of Storozhev. The monastery late flourished under the reign of Tsar Alexis, who chose the monastery as his family church and often went on pilgrimage there and made lots of donations to it. Most of the monastery’s buildings date from this time. The monastery is heavily fortified with thick walls and six towers, the most impressive of which is the Krasny Tower which also serves as the eastern entrance. The monastery was closed in 1918 and only reopened in 1995. In 1998 Patriarch Alexius II took part in a service to return the relics of St Sabbas to the monastery. Today the monastery has the status of a stauropegic monastery, which is second in status to a lavra. In addition to being a working monastery, it also holds the Zvenigorod Historical, Architectural and Art Museum.

Belfry and Neighbouring Churches

Located near the main entrance is the monastery's belfry which is perhaps the calling card of the monastery due to its uniqueness. It was built in the 1650s and the St Sergius of Radonezh’s Church was opened on the middle tier in the mid-17th century, although it was originally dedicated to the Trinity. The belfry's 35-tonne Great Bladgovestny Bell fell in 1941 and was only restored and returned in 2003. Attached to the belfry is a large refectory and the Transfiguration Church, both of which were built on the orders of Tsar Alexis in the 1650s.  

To the left of the belfry is another, smaller, refectory which is attached to the Trinity Gate-Church, which was also constructed in the 1650s on the orders of Tsar Alexis who made it his own family church. The church is elaborately decorated with colourful trims and underneath the archway is a beautiful 19th century fresco.

Nativity of Virgin Mary Cathedral

The Nativity of Virgin Mary Cathedral is the oldest building in the monastery and among the oldest buildings in the Moscow Region. It was built between 1404 and 1405 during the lifetime of St Sabbas and using the funds of Prince Yury of Zvenigorod. The white-stone cathedral is a standard four-pillar design with a single golden dome. After the death of St Sabbas he was interred in the cathedral and a new altar dedicated to him was added.

Under the reign of Tsar Alexis the cathedral was decorated with frescoes by Stepan Ryazanets, some of which remain today. Tsar Alexis also presented the cathedral with a five-tier iconostasis, the top row of icons have been preserved.

Tsaritsa's Chambers

The Nativity of Virgin Mary Cathedral is located between the Tsaritsa's Chambers of the left and the Palace of Tsar Alexis on the right. The Tsaritsa's Chambers were built in the mid-17th century for the wife of Tsar Alexey - Tsaritsa Maria Ilinichna Miloskavskaya. The design of the building is influenced by the ancient Russian architectural style. Is prettier than the Tsar's chambers opposite, being red in colour with elaborately decorated window frames and entrance.

At present the Tsaritsa's Chambers houses the Zvenigorod Historical, Architectural and Art Museum. Among its displays is an accurate recreation of the interior of a noble lady's chambers including furniture, decorations and a decorated tiled oven, and an exhibition on the history of Zvenigorod and the monastery.

Palace of Tsar Alexis

The Palace of Tsar Alexis was built in the 1650s and is now one of the best surviving examples of non-religious architecture of that era. It was built especially for Tsar Alexis who often visited the monastery on religious pilgrimages. Its most striking feature is its pretty row of nine chimney spouts which resemble towers.

Plan your next trip to Russia

Ready-to-book tours.

Your holiday in Russia starts here. Choose and book your tour to Russia.

REQUEST A CUSTOMISED TRIP

Looking for something unique? Create the trip of your dreams with the help of our experts.

Amazon Ads announces three new Streaming TV ad formats ahead of debut upfront presentation

May 07, 2024